Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

5.12USD
20 Apr 2018
Change (% chg)

$0.05 (+0.99%)
Prev Close
$5.07
Open
$5.05
Day's High
$5.21
Day's Low
$4.97
Volume
176,085
Avg. Vol
501,563
52-wk High
$8.61
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Tuesday, 6 Sep 2016 

Proteostasis Therapeutics Inc :Files to say it is offering 4.3 million shares of its common stock.  Full Article

Proteostasis Therapeutics files for common stock offering
Thursday, 25 Aug 2016 

Proteostasis Therapeutics Inc : Files for common stock offering of up to $60 million - SEC filing Source: (http://bit.ly/2bDxfUB) Further company coverage: [PTI.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Proteostasis Therapeutics achieves preclinical milestone in Astellas Pharma collaboration . Says milestone demonstrated selective modulation of UPR pathway in vitro . Says milestone triggered an undisclosed payment from Astellas . Astellas retains right to begin 2 additional projects, which, if fully exercised would bring potential value of collaboration to $1.2 billion .As a result of preclinical milestone, co eligible for further milestone payments, which could result in total payments of over $400 million.  Full Article

Proteostasis Therapeutics says appointment of James M. Detore as CFO
Monday, 8 Aug 2016 

Proteostasis Therapeutics Inc : Says appointment of James M. Detore as Chief Financial Officer .Detore joins company from Bluebird Bio, Inc.  Full Article

BRIEF-Proteostasis Receives Endorsement From Cystic Fibrosis Foundation For Study Of PTI-428 In CF Subjects On Background Symdeko Therapy

* PROTEOSTASIS RECEIVES ENDORSEMENT FROM THE CYSTIC FIBROSIS FOUNDATION'S THERAPEUTIC DEVELOPMENT NETWORK FOR THE STUDY OF THE COMPANY'S AMPLIFIER, PTI-428, IN CF SUBJECTS ON BACKGROUND SYMDEKO™ THERAPY Source text for Eikon: Further company coverage: